With the introduction of panel and direct-to-consumer (DTC) testing, genetic testing has become commonplace in recent years. Although this has paved the way for increased awareness around prevalent genetic cancer risks, it also allows for an onslaught of misinformation. At the NCCN 2020 Virtual Annual Conference, Tuya Pal, MD, Professor of Medicine, Vanderbilt-Ingram Cancer Center, led a panel of experts in discussing the utility and difficulties associated with multigene testing, the emerging role of moderate-penetrance genes in defining risks for hereditary cancer, and the controversies associated with direct-to-consumer genetic testing services.
Lubbe SJ, Di Bernardo MC, Chandler IP, Clinical implication of the colorectal cancer risk associated with MUTYH mutation. J Clin Oncol 2009;27:3975–3980.
Win AK, Dowty JG Cleary SP, Risk of colorectal cancer for carriers of mutations in MUTYH, with and without a family history of cancer. Gastroenterology 2014;146:1208–1211.
Katona BW, Yurgelun MB, Garber JE, A counseling framework for moderate-penetrance colorectal cancer susceptibility genes. Genet Med 2018;20:1324–1327.
Katona BW, Stadler ZK, Robson ME, RE: BRCA1 and BRCA2 gene mutations and colorectal cancer risk: systematic review and meta-analysis. J Natl Cancer Inst 2019;111:522–523.
Kilbride MK, Joffe S. The new age of patient autonomy: implications for the patient-physician relationship. JAMA 2018;320:1973–1974.